Lavoisier S.A.S.
14 rue de Provigny
94236 Cachan cedex

Heures d'ouverture 08h30-12h30/13h30-17h30
Tél.: +33 (0)1 47 40 67 00
Fax: +33 (0)1 47 40 67 02

Url canonique :
Url courte ou permalien :

Oral Bioavailability Assessment Basics and Strategies for Drug Discovery and Development Wiley Series on Pharmaceutical Science and Biotechnology: Practices, Applications and Methods Series

Langue : Anglais

Auteur :

Directeur de Collection : Lee Mike S.

Couverture de l’ouvrage Oral Bioavailability Assessment
Specifically geared to personnel in the pharmaceutical and biotechnology industries, this book describes the basics and challenges of oral bioavailability – one of the most significant hurdles in drug discovery and development.

•    Describes approaches to assess pharmacokinetics and how drug efflux and uptake transporters impact oral bioavailability
•    Helps readers reduce the failure rate of drug candidates when transitioning from the bench to the clinic during development
•    Explains how preclinical animal models – used in preclinical testing – and in vitro tools translate to humans, which is an underappreciated and complicated area of drug development
•    Includes chapters about pharmacokinetic  modelling, the Biopharmaceutics Drug Disposition Classification System (BDDCS), and the Extended Clearance Classification System (ECCS)
•    Has tutorials for applying strategies to medicinal chemistry practices of drug discovery/development
- 1. Drug Pharmacokinetics and Toxicokinetics
- 2. GIT Anatomy and Physiology and Drug Oral Bioavailability: Impact of Species Differences
- 3. Drug Routes of Excretion
- 4. Physicochemical and Biopharmaceutical Properties that Affect Drug Absorption of Compounds Absorbed by Passive Diffusion
- 5. Physicochemical and Biopharmaceutical Factors Affecting Hepatic/Intestinal First-Pass Effect
- 6. Impact of Intestinal Efflux Transporters on Oral Absorption
- 7. Impact of Influx Transporters on Drug Absorption
- 8. Extended Clearance Classification System (ECCS) and its Utility in Predicting Clearance Rate-Determining Step in Drug Discovery
- 9. In Vitro and In Situ Approaches to Measure Intestinal Permeability and Efflux Transporters
- 10. In Silico Approaches to Predict Intestinal Permeability
- 11. In Vivo Preclinical Approaches to Deconvolute The Contribution of First-Pass Effect from Oral Absorption
- 12. In Vitro Approaches to Assess Hepatic Metabolism and First-Pass Effect
- 13. The Utility of ECCS as a Roadmap to Improve Oral Bioavailability of New Molecular Entities: Industrial Perspective
- Index
Ayman F. El-Kattan, B. Pharm, PhD, is Associate Research Fellow in Pfizer's Pharmacokinetics, Dynamics, and Metabolism Department, Cambridge Laboratories and an Adjunct Professor at College of Pharmacy-University of Rhode Island in Rhode Island, US.

Date de parution :

Ouvrage de 436 p.

15.7x24.1 cm

Disponible chez l'éditeur (délai d'approvisionnement : 12 jours).

Prix indicatif 183,90 €

Ajouter au panier
En continuant à naviguer, vous autorisez Lavoisier à déposer des cookies à des fins de mesure d'audience. Pour en savoir plus et paramétrer les cookies, rendez-vous sur la page Confidentialité & Sécurité.